Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 4/20 | 0.38 |
| ▸ | HRH1 | P35367 | 4/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30164348 | 0.91 | CTSK (0.47) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL24036902 | 0.89 | CTSK (0.53) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL21584005 | 0.89 | CTSK (0.53) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL24443965 | 0.87 | CTSK (0.46) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL24690239 | 0.86 | KCNA3 (0.54) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL24098366 | 0.86 | CA1 (0.49) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL31420976 | 0.85 | CTSK (0.47) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL24037096 | 0.85 | CTSK (0.36) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL25235574 | 0.85 | CTSK (0.36) | CTSKBTKCA1CA2DRD2 | |
| SCHEMBL25529790 | 0.85 | CTSK (0.36) | CTSKBTKCA1CA2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577534-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577531-A1 | NOVEL SUBSTITUTED 2-CARBONYL-BENZOTHIOPHENE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| CN-119907798-A | Novel substituted 2,3,4, 9-tetrahydro-1H-pyrido [3,4-B ] indolecarboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-29 | — | — | CN | disclosed |
| CN-119790048-A | Novel substituted tetrahydroisoquinoline-6-carboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-08 | — | — | CN | disclosed |
| CN-119790046-A | Novel substituted 2-carbonyl-benzothiophene-6-carboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-08 | — | — | CN | disclosed |
| US-20240383895-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-12077530-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2024-09-03 | — | — | US | disclosed |
| US-11999728-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024042152-A1 | NOVEL SUBSTITUTED 2-CARBONYL-BENZOTHIOPHENE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042163-A1 | NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-10590130-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-17 | — | — | US | disclosed |
| WO-2019228443-A1 | SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2019-12-05 | — | — | WO | disclosed |
| WO-2019157020-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-3433256-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-04-04 | — | — | US | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239467-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
| US-12077530-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
| US-10590130-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
| US-11999728-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | CTSK 3987/4885BTK 3119/4885CA1 2591/4885 |
| US-20240383895-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CTSK 2864/4885BTK 3084/4885CA1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.